Tanvex BioPharma Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Stephen Lam

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.1yrs

Jüngste Management Updates

Recent updates

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Aug 07

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24

Geschäftsführer

Stephen Lam

no data

Amtszeit

Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Stephen Lam	Chief Executive Officer	no data	keine Daten	keine Daten
Allen Chao	Founder & Honorary Chairman	no data	NT$111.00k	0.87% NT$ 99.4m
Wen Yeh	Chief Financial Officer	less than a year	keine Daten	keine Daten
Val Chen	VP of Finance Director of Ops. Mgmt.	no data	keine Daten	keine Daten
James Williamson	Accounting Officer	less than a year	keine Daten	keine Daten
Zheng Xia	Chief Technology Officer	9.8yrs	keine Daten	keine Daten
Linda Grillo	Director of Sales & Marketing	no data	keine Daten	keine Daten
Hsun-Chiang Hsieh	Secretary	no data	keine Daten	keine Daten

0.7yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: 6541Das Führungsteam des Unternehmens gilt nicht als erfahren ( 0.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Allen Chao	Founder & Honorary Chairman	11.3yrs	NT$111.00k	0.87% NT$ 99.4m
David Hsia	Director	9.3yrs	keine Daten	0.50% NT$ 56.6m
Lin-Cheng Chen	Chairman	less than a year	NT$5.00k	keine Daten
Chi-Chuan Chen	Director	10.9yrs	NT$25.00k	0.010% NT$ 1.1m
Tamon Tseng	Director	10.9yrs	NT$25.00k	keine Daten
Jin-Pau Tsai	Independent Director	9.3yrs	NT$682.00k	keine Daten
Tay-Chang Wang	Independent Director	3.1yrs	NT$687.00k	keine Daten
Jang-Yang Chang	Independent Director	2.3yrs	NT$570.00k	keine Daten
Shang-Hsien Hsieh	Independent Director	less than a year	keine Daten	keine Daten
Chi-feng Chang	Independent Director	less than a year	keine Daten	keine Daten
Chun-Yen Chang	Independent Director	2.3yrs	NT$622.00k	keine Daten

3.1yrs

Durchschnittliche Betriebszugehörigkeit

72yo

Durchschnittliches Alter

Erfahrener Vorstand: 6541Die Vorstandsmitglieder gelten als erfahren (6.1 Jahre durchschnittliche Amtszeit).

Tanvex BioPharma Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Recent updates

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

Second quarter 2024 earnings released: NT$2.31 loss per share (vs NT$3.89 loss in 2Q 2023)

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Tanvex BioPharma, Inc. to Report Q2, 2024 Results on Aug 09, 2024

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

First quarter 2024 earnings released: NT$3.12 loss per share (vs NT$5.17 loss in 1Q 2023)

Tanvex BioPharma, Inc. to Report Q1, 2024 Results on May 07, 2024

Tanvex BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of TWD 1.44 billion.

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: NT$16.58 loss per share (vs NT$13.96 loss in FY 2022)

New major risk - Financial position

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer

Tanvex BioPharma, Inc. Announces Change of Chairman

Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer

Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer

Tanvex BioPharma, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Second quarter 2023 earnings released: NT$3.89 loss per share (vs NT$3.63 loss in 2Q 2022)

New minor risk - Shareholder dilution

Tanvex BioPharma, Inc. announced that it expects to receive TWD 220 million in funding

Less than half of directors are independent

Tanvex BioPharma, Inc. announced a financing transaction

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

Less than half of directors are independent

Tanvex BioPharma, Inc., Annual General Meeting, Jun 17, 2022

Tanvex BioPharma, Inc. Announces the Appointment of K. H. Lin as CFO and Accounting Officer, Effective from February 18, 2022

Price target decreased to NT$53.00

Price target increased to NT$67.00

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Tanvex BioPharma, Inc. Enters into A License Agreement with Amgen

New 90-day high: NT$44.95

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

New 90-day low: NT$36.55

New 90-day low: NT$37.15

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

New 90-day high: NT$45.95

Earnings miss expectations

New 90-day low - NT$37.00

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter